More about

Advanced Liver Fibrosis

News
May 01, 2025
3 min read
Save

Semaglutide tied to significant improvements in MASH, liver fibrosis at 72 weeks

Once-weekly semaglutide 2.4 mg significantly reduced steatohepatitis and liver fibrosis symptoms among adults with metabolic dysfunction-associated steatohepatitis and moderate or advanced liver fibrosis, researchers reported.

News
June 23, 2023
1 min read
Save

Intercept pivots away from NASH following second FDA rejection for obeticholic acid

  The FDA issued a complete response letter to Intercept indicating it cannot approve the company’s new drug application for obeticholic acid as a treatment for pre-cirrhotic liver fibrosis due to nonalcoholic steatohepatitis.

News
September 20, 2021
2 min read
Save

Icosabutate rapidly reduces biomarkers of liver injury in NASH

Two doses of icosabutate were well tolerated and safe in patients with nonalcoholic steatohepatitis.

News
September 17, 2021
2 min read
Save

Longitudinal fat fraction, liver stiffness may signal rapid progression in NAFLD

The temporal change rate of proton density fat fraction and liver stiffness measurement are promising predictors for those at high risk for rapid clinical progression and may improve patient management in those with nonalcoholic fatty liver disease.

News
July 09, 2021
2 min read
Save

Q&A: TERN-101 may be tolerable in patients with NASH

Terns Pharmaceuticals Inc. announced positive topline results from the phase 2a Lift study of TERN-101 for the treatment of patients with nonalcoholic steatohepatitis.

News
June 28, 2021
2 min read
Save

Elastography, bloodwork combine for ‘super test’ to diagnose advanced liver fibrosis

Using clinical bloodwork like FIB-4 and elastography technology in combination, Researchers at the International Liver congress proposed they could better identify patients with advanced fibrosis using clinical bloodwork like FIB-4 and elastography technology in combination.